Eris Lifesciences will be assigned the trademark of these brands by Dr. Reddy's for a consideration of Rs. 275 crore
Operating EBITDA grew by 82.7 % to Rs. 14.4 crore, EBITDA margin at 23.9%, and Profit After Tax (PAT) grew by 47.1% to Rs. 7.8 crore
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations
Honan will lead the company in identifying and executing acquisitions that complement Emmes’ existing strong federal government client base, expand its biopharma portfolio, enhance its technology offerings, and broaden its global reach
The company is one of the most profitable companies manufacturing speciality chemicals in India
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Proceeds from the transaction will be reinvested towards the growth, innovation and expansion of Healthium’s advanced surgery, orthopaedics, wound care and post-surgical care portfolio
The company sees the business reaching $100mn
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
Subscribe To Our Newsletter & Stay Updated
